NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n = 1,886) vs. long-term DAPT (18 months; n = 1,887). (p = 0.24) Results Incidence of all-cause mortality, myocardial infarction, stroke, or major bleeding: 2.1% of the short-term DAPT group versus 1.5% of the long-term DAPT group (p = 0.24) Stent thrombosis: 0.1% vs. 0.1% (p = 0.99), respectively for short-term vs. long-term DAPT Major bleeding: 0.7% vs. 0.7% (p = 0.99), respectively for short-term vs. long-term DAPT 2.1 1.5 % Conclusions Among patients undergoing treatment with a biodegradable polymer drug-eluting stent, short-term DAPT (6 months) was noninferior to long-term DAPT therapy (18 months) Short-term DAPT Long-term DAPT Nakamura M, et al. JACC Cardiovasc Interv 2017;10:1189-98